<DOC>
	<DOCNO>NCT02969070</DOCNO>
	<brief_summary>Hypercholesterolemia consider one important cardiovascular risk factor . Cardiovascular prevention include class I indication statin addition non-pharmacologic intervention prevention strategy patient deem 'high risk ' . Along non-pharmacologic intervention prevention strategy , new approach reduce cholesterol blood level currently include nutraceuticals , compound derive food cholesterol lower action . However , remain unclear nutraceuticals yield additive positive effect cholesterol lower . In particular , evidence Berberine cardiovascular protective effect , vitro , Morus Alba , mulberry fruit , modulate platelet function inhibit platelet activation , thromboxane formation , serotonin secretion , aggregation thrombus formation . Furthermore , Morus Alba exert α-glucosidase inhibitory antioxidant activity vitro , may reduce postprandial glucose peak , thus improve HbA1c concentration . Accordingly , designate study evaluate effect two commercially available nutraceutical combine pill [ LopiGLIK™ , Akademy Pharma , 1 capsule/day contain red yeast rice 220 mg ( least 3,3 mg Monacolin K ) + Berberine 531,25 mg + Morus Alba 200 mg ( least 4 mg Deoxynojirimycin ) vs. Armolipid Plus® , Meda Pharma , 1 capsule/day contain Berberis aristata d.e . 588 mg ( equivalent Berberine chloride 500 mg ) + Red yeast rice 200 mg ( equivalent Monacolin K 3 mg ) + Policosanol 10 mg + Folic acid 0.2 mg + Coenzyme Q10 2.0 mg + Astaxanthin 0.5 mg ] lipid metabolic profile , platelet aggregation , endothelial function coronary flow reserve ( CFR ) . For purpose patient hypercholesterolemia require statin statin intolerant moderate cardiovascular risk subject day 0 day 28 , 4 week therapy , blood sample evaluate lipid metabolic profile , peripheral arterial tonometry ( EndoPAT ) , platelet aggregation test light transmission aggregometry ( LTA ) , nitric oxide ( NO ) release , endothelial nitric oxide synthase ( eNOS ) phosphorylation platelet . Only CFR , patient evaluate also two hour administration first dose nutraceutical combine pill . Patients randomly assign receive therapy LopiGLIK™ Armolipid Plus® .</brief_summary>
	<brief_title>Effects Nutraceutical Therapies Endothelial Function , Platelet Aggregation , Coronary Flow Reserve</brief_title>
	<detailed_description>Cardiovascular disease ( CVD ) principal cause death worldwide . Primary prevention cardiovascular disease identify treat at-risk individual remain major public-health priority . According guideline , main approach healthy life-style , assisted pharmaco-therapy . Hypercholesterolemia consider one important cardiovascular risk factor . Cardiovascular prevention include class I indication statin addition non-pharmacologic intervention prevention strategy patient deem 'high risk ' . In real world , however , statin treatment often discontinue due side effect . In addition , statin indicate subject deem 'low risk ' , non-pharmacologic intervention prevention strategy currently prescribe . Along non-pharmacologic intervention prevention strategy , new approach reduce cholesterol blood level currently include nutraceuticals , compound derive food cholesterol lower action . However , remain unclear nutraceuticals yield additive positive effect cholesterol lower . In particular , evidence Berberine cardiovascular protective effect , vitro , Morus Alba , mulberry fruit , modulate platelet function inhibit platelet activation , thromboxane formation , serotonin secretion , aggregation thrombus formation . Furthermore , Morus Alba exert α-glucosidase inhibitory antioxidant activity vitro , may reduce postprandial glucose peak , thus improve HbA1c concentration . Accordingly , designate study evaluate effect two commercially available nutraceutical combine pill [ LopiGLIK™ , Akademy Pharma , 1 capsule/day contain red yeast rice 220 mg ( least 3,3 mg Monacolin K ) + Berberine 531,25 mg + Morus Alba 200 mg ( least 4 mg Deoxynojirimycin ) vs. Armolipid Plus® , Meda Pharma , 1 capsule/day contain Berberis aristata d.e . 588 mg ( equivalent Berberine chloride 500 mg ) + Red yeast rice 200 mg ( equivalent Monacolin K 3 mg ) + Policosanol 10 mg + Folic acid 0.2 mg + Coenzyme Q10 2.0 mg + Astaxanthin 0.5 mg ] lipid metabolic profile , platelet aggregation , endothelial function coronary flow reserve ( CFR ) . For purpose patient hypercholesterolemia require statin statin intolerant moderate cardiovascular risk subject day 0 day 28 , 4 week therapy , blood sample evaluate lipid metabolic profile , peripheral arterial tonometry ( EndoPAT ) , platelet aggregation test light transmission aggregometry ( LTA ) , NO release , eNOS phosphorylation platelet . Only CFR , patient evaluate also two hour administration first dose nutraceutical combine pill . Patients randomly assign receive therapy LopiGLIK™ Armolipid Plus® . STUDY DESIGN Study procedure For study enrolment , subject undergo screen determine criterion inclusion / exclusion study . Eligible patient receive information sheet give preview family General Practitioner , , accept participate , must sign write informed consent . The information collect subject , regard suitability study , retain stored Investigators . Condition Outcomes Intervention Patients hypercholesterolemia moderate cardiovascular risk accord current European Society Cardiology ( ESC ) guideline Device : Peripheral arterial tonometry ( EndoPAT ) Device : Platelet aggregation LTA Platelet isolation measurement eNOS phosphorylation Device : colorDoppler echocardiography rest cold pressure test CFR evaluation 4 week LopiGLIK™ therapy 1 capsule/day 4 week Armolipid Plus® therapy 1 capsule/day Study Type : Interventional Study plan : - 30 patient evaluate day 0 ( anamnesis , cardiovascular risk factor , medication , EndoPAT + CFR + blood sample ( 1 yellow tube biochemistry + 6 light blue tube platelet function ) - Patients randomly assign treatment 4 week 1 capsule/day LopiGLIK™ containing red yeast rice 220 mg + Berberine 531,25 mg + Morus Alba 200 mg 1 capsule/day Armolipid Plus® contain Berberis aristata d.e . 588 mg ( equivalent Berberine chloride 500 mg ) + Red yeast rice 200 mg ( equivalent Monacolin K 3 mg ) + Policosanol 10 mg + Folic acid 0.2 mg + Coenzyme Q10 2.0 mg + Astaxanthin 0.5 mg - Re-evaluation day 28 test perform day 0 Primary Outcome Measures : • Effects endothelial function evaluate Reactive Hyperemia Index ( RHI ) Secondary Outcome Measures : - Evaluation treatment tolerability ( evaluate specific questionnaire ) - Reasons treatment discontinuation - Effects lipid profile ( total cholesterol , LDL cholesterol , HDL cholesterol , triglyceride ) metabolic index ( glucose level , insulin plasma level , insulin sensitivity index ( HOMA index ) - Effects platelet aggregation evaluate LTA - Effects coronary flow reserve ( CFR ) evaluate echocardiocolorDoppler visualization coronary flow distal leave anterior descend artery rest cold pressure test ( CPT ) . STUDY POPULATION Eligibility : Ages Eligible Study : 18 Years 70 Years Genders Eligible Study : Both Accepts Healthy Volunteers : yes Enrollment : 30 patient METHODS Endothelial function Endothelial function assess flow-mediated dilation test ( FMD ) digital pulse amplitude , use fingertip PAT previously describe [ Gargiulo P , et al . Int J Cardiol 2013 ] . The system ( Itamar Medical Ltd. , Caesarea , Israel ) consist finger probe assess digital volume change accompany pulse wave . All subject include study maintain without smoking , alcohol caffeine night evaluation . Reactive hyperaemia measure PAT reactive hyperaemic index ( RHI ) calculate ratio average amplitude PAT signal 1-min time interval start 1-min cuff deflation divide average amplitude PAT signal 3.5-min time period cuff inflation ( baseline ) normalize RHI control arm . Endothelial dysfunction define RHI &lt; 1.68 calculate mean value minus 2 standard deviation 20 healthy asymptomatic control individual without history cardiovascular disease without major cardiovascular risk factor previously describe [ Gargiulo P , et al . Int J Cardiol 2013 ] . Platelet function Platelet aggregation measure light transmission aggregometry ( LTA ) use dual channel lumi-aggregometer ( model 700 ; Chrono-Log ) . Platelets prepare accord standard procedure . Briefly , platelet-rich plasma ( PRP ) prepare blood drawn venipuncture 3.8 % trisodium citrate ( w/v ) Vacutainer Blood Collection Tubes . PRP obtain centrifugation blood 250 g 25°C 15 minute . Platelet-poor plasma ( PPP ) obtain centrifugation rest blood 1400 g 25°C 10 minute . Platelet aggregation monitor 37°C constant stirring ( 1200 rpm ) measure increase light transmission 10 minute , addition adenosine diphosphate ( ADP ) 10 μmol/L , collagen 2 μg/ml arachidonic acid 1 0,5 millimole ( mM ) proaggregatory stimulus . All measurement obtain within 2 hour sample collection , result report percentage maximum aggregation . Some experiment perform platelet pre-treated insulin ( 15 microIU/mL ) 30 minute 37°C . After stimulation , 3 ml platelet suspension centrifuge 15 minute 3000 platelet pellet obtain use measurement eNOS phosphorylation NO level . Coronary flow reserve Standard Doppler echocardiography perform use Vivid Seven machine ( GE , Horten , Norway ) morning overnight fast 12-14 h ; subject instruct avoid coffee-containing drink theophylline contain medication , abstain smoke heavy exercise 24 h study . The color Doppler visualization coronary flow distal leave anterior descend artery obtain 5 megahertz ( MHz ) shallow-focus phased-array transducer . Doppler sample volume place color signal leave anterior descend artery , spectral pulse Doppler signal record look characteristic biphasic flow pattern large diastolic small systolic component rest cold pressure test ( CPT ) . Coronary diastolic peak flow velocity ( cm/s ) well heart rate BP measure rest soon CPT , correspond maximal hyperemia . CFR calculate ratio hyperemic-to-resting diastolic peak velocity . The CPT perform accord standardize protocol [ Marciano C , Eur J Nucl Med Mol Imaging 2012 ] , place subject 's hand distal part forearm ice water slurry 3 min . The high three spectral Doppler signal average parameter . CFR evaluate baseline , 2 hour administration first nutraceutical combine pill , 28 day therapy . All image record local archive analyze off-line two observer blind clinical characteristic patient . Sample size calculation Assuming standard deviation difference Endo-PAT index 2 test day would 0.5 would want detect true difference mean &gt; 0.5 paired test conduct 0.05 level significance , determine sample 30 subject ( 15 group ) would provide 80 % power . Composition supply nutraceutical treatment Capsules LopiGLIK™ ( contain red yeast rice 220 mg + Berberine 531,25 mg + Morus Alba 200 mg ) Armolipid Plus® ( contain Berberis aristata d.e . 588 mg ( equivalent Berberine chloride 500 mg ) + Red yeast rice 200 mg ( equivalent Monacolin K 3 mg ) + Policosanol 10 mg + Folic acid 0.2 mg + Coenzyme Q10 2.0 mg + Astaxanthin 0.5 mg ) provide free charge Akademy Pharma Meda Pharma , respectively . Treatment duration All patient treat period 4 week . Data Results study communicate participant study end .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>1 . Age 1870 year old 2 . Patients hypercholesterolemia moderate cardiovascular risk accord current ESC guideline ( risk fatal cardiovascular event 19 % 10 year accord SCORE risk chart lowrisk population ) 3 . Patients give write Informed Consent . 1 . Statin treatment indication 2 . Previous cardiovascular event 3 . Diabetes mellitus 4 . Creatinine Clearance &lt; 60ml/min/1.73mm2 5 . Moderate severe anemia Hb &lt; 10mg/dl 6 . Platelet count &gt; 600 x 103/mm3 &lt; 150 x 103/mm3 hematocrit ( HCT ) &gt; 50 % &lt; 25 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>